Bladder Cancer: Symptoms, Diagnosis and Treatment

Bladder cancer is the tenth most common cancer worldwide, with approximately 570,000 new cases and 210,000 deaths annually. It predominantly affects men (3–4× higher incidence than women) and the median age at diagnosis is approximately 73. It is notably the most expensive cancer to treat per patient over a lifetime — due to the requirement for lifelong cystoscopic surveillance following treatment for non-muscle-invasive disease.

The incidence of bladder cancer in China is rising, partly due to ageing demographics, continued high smoking rates, and increasing occupational and environmental exposures. Bladder cancer accounts for approximately 5% of all cancers in Chinese men.

Types of Bladder Cancer

Urothelial Carcinoma (Transitional Cell Carcinoma — TCC)

Accounts for approximately 90% of all bladder cancers in Western countries (and >80% in China). Arises from the transitional epithelium (urothelium) lining the entire urinary tract — from the renal pelvis through the ureters, bladder, and urethra. The bladder is the most common site.

Urothelial carcinoma may also arise in the upper urinary tract (renal pelvis, ureter) — termed upper tract urothelial carcinoma (UTUC) — managed differently but with the same pathological principles.

Other Types

• Squamous cell carcinoma (~5%) — associated with chronic bladder inflammation (catheterisation, schistosomiasis infection — common in Middle East/Africa); tends to be muscle-invasive at diagnosis
• Adenocarcinoma (~2%) — rare; may arise from urachal remnants or bladder exstrophy
• Small cell carcinoma — very rare; aggressive; treated similarly to small cell lung cancer
• Sarcoma / lymphoma — extremely rare primary bladder tumours

The Critical Staging Distinction: NMIBC vs MIBC

The most important clinical distinction in bladder cancer management:

	Non-Muscle-Invasive Bladder Cancer (NMIBC)	Muscle-Invasive Bladder Cancer (MIBC)
Stage	Ta, T1, CIS	T2–T4
Invasion	Confined to mucosa/lamina propria; does not penetrate detrusor muscle	Invades detrusor muscle (T2) or beyond
Proportion	~75% at diagnosis	~25% at diagnosis
Treatment	Transurethral resection (TURBT) + intravesical therapy	Radical cystectomy or radiotherapy
5-year survival	85–95% (low-risk); 50–70% (high-risk)	50–60% (T2); 20–30% (T3–4)
Surveillance	Lifelong cystoscopic follow-up required	Follow-up for recurrence and metastasis

Carcinoma in situ (CIS): flat, high-grade urothelial lesion confined to the mucosa; may not be visible on cystoscopy; multifocal; high risk of progression to MIBC without treatment; classified as high-risk NMIBC.

Causes and Risk Factors

Smoking

The dominant modifiable risk factor — responsible for approximately 50% of bladder cancer cases. Cigarette smoking increases bladder cancer risk approximately 4-fold; pipe and cigar smoking confer equivalent risk. Carcinogenic arylamines and nitrosamines in tobacco are excreted by the kidney, concentrated in urine, and remain in prolonged contact with the urothelium. Smoking cessation reduces risk over time but the excess risk never fully returns to baseline.

Occupational Carcinogens

Aromatic amines used in chemical, dye, rubber, textile, leather, and paint industries. The classic occupational exposure is 2-naphthylamine and benzidine — historically used in dye manufacture. Risk remains elevated for 20–40 years after exposure. Current occupational exposure is regulated in most countries, but legacy exposure remains a significant source.

Chronic Irritation and Inflammation

• Urinary schistosomiasis (Schistosoma haematobium) — endemic in Africa and Middle East; eggs deposited in the bladder wall cause chronic inflammation; associated with squamous cell carcinoma rather than TCC
• Chronic indwelling urinary catheterisation — long-term catheter use in spinal cord injury
• Recurrent UTIs — chronic bacterial cystitis contributes marginally

Other Risk Factors

• Age — strong age association; median diagnosis 73 years
• Male sex — 3–4× higher than female; partly explained by higher smoking rates historically but likely also hormonal and metabolic factors
• Pelvic radiotherapy — prior radiation for prostate, cervical, or rectal cancer increases bladder cancer risk 2–4× after 10+ years
• Cyclophosphamide chemotherapy — alkylating agent metabolite acrolein is directly toxic to urothelium; increases transitional cell carcinoma risk
• Arsenic exposure — drinking water contamination in parts of Asia and South America
• Family history — small increased risk; FGFR3 and other genetic variants confer susceptibility

Symptoms

Haematuria (Blood in Urine)

The cardinal and most important symptom — present in approximately 85–90% of patients at diagnosis.

Macroscopic haematuria (frank blood visible in urine): a single episode of painless macroscopic haematuria in any adult over 40 mandates urgent investigation with cystoscopy — the probability of underlying bladder cancer is approximately 20–25% in this presentation.

Microscopic haematuria (blood detectable on urinalysis only, not visible): found on routine urinalysis or dipstick; in adults over 40 with no obvious benign cause (UTI, vigorous exercise), warrants investigation.

Haematuria in bladder cancer is classically:

• Painless — distinguishes it from UTI-related haematuria (which is usually painful)
• Intermittent — may be present in one sample and absent for weeks; does not exclude cancer
• Total (blood present throughout the urine stream) — suggests a bladder or upper tract source rather than urethra

Other Symptoms

Storage LUTS (urgency, frequency, dysuria) — may indicate CIS (carcinoma in situ), which causes bladder irritability without a visible lesion.

Flank pain / loin pain — ureteric obstruction by a tumour near the ureteric orifice or upper tract disease.

Pelvic pain, bone pain, leg oedema — features of locally advanced or metastatic disease.

Bladder cancer may also be an incidental finding on imaging (CT, ultrasound) performed for another indication.

Diagnosis and Staging

Cystoscopy

The essential diagnostic investigation. A rigid or flexible cystoscope is passed via the urethra into the bladder under local anaesthesia (flexible) or general anaesthesia (rigid) — providing direct visualisation of the urothelium and any suspicious lesions.

Flexible cystoscopy — outpatient procedure under local urethral anaesthesia; standard initial investigation for haematuria; identifies visible lesions but does not allow biopsy.

Rigid cystoscopy + TURBT — under general or spinal anaesthesia; allows simultaneous resection of visible tumours (see TURBT, below).

Enhanced cystoscopy techniques improve detection of flat lesions (CIS):

• Photodynamic diagnosis (PDD / blue light cystoscopy): hexaminolevulinate instilled intravesically accumulates selectively in tumour cells, which fluoresce red under blue light — detects CIS and flat lesions missed by standard white-light cystoscopy in approximately 20–30% of cases
• Narrow-band imaging (NBI): optical filter enhances contrast of mucosal vasculature; improves detection of small and flat tumours

Transurethral Resection of Bladder Tumour (TURBT)

The principal diagnostic and therapeutic procedure for bladder tumours. Under general or spinal anaesthesia, the resectoscope is passed cystoscopically; the tumour is resected down to detrusor muscle and sent for histological analysis.

Histological analysis provides:

• Cell type — urothelial, squamous, adenocarcinoma
• Grade — low-grade (slow-growing, low recurrence risk) or high-grade (aggressive, high recurrence and progression risk)
• Depth of invasion (T stage) — presence or absence of muscularis propria (detrusor) invasion is critical
• Presence of CIS

Re-TURBT (second-look TURBT): performed 4–6 weeks after initial TURBT for all T1 high-grade tumours (because residual tumour and understaging occur in 30–50% of cases) and whenever muscle was absent in the initial specimen.

CT Urography (CTU)

CT of the kidneys, ureters, and bladder with contrast — evaluates the upper urinary tract for synchronous urothelial tumours (occur in 2–5% of bladder cancer patients); assesses for pelvic lymph node enlargement and distant metastases in staging of MIBC.

Urinary Cytology

Microscopic examination of urothelial cells in a voided urine specimen. High sensitivity for high-grade TCC and CIS but low sensitivity for low-grade tumours. Useful as an adjunct to cystoscopy and for surveillance.

Staging (TNM)

Stage	Description
Ta	Non-invasive papillary tumour
CIS	Flat high-grade intraepithelial carcinoma
T1	Invades lamina propria (subepithelial connective tissue)
T2a	Invades inner half of detrusor muscle
T2b	Invades outer half of detrusor muscle
T3	Invades perivesical tissue
T4	Invades adjacent organs (prostate, uterus, pelvic wall)
N1–N3	Regional lymph node involvement
M1	Distant metastasis (bone, lung, liver)

Risk stratification for NMIBC (EAU guidelines):

• Low-risk: single Ta low-grade tumour, <3 cm, no CIS
• Intermediate-risk: multiple or recurrent Ta low-grade; low-grade T1
• High-risk: T1 high-grade; CIS; high-grade Ta; large multifocal tumours

Treatment

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Single Instillation Intravesical Chemotherapy (Post-TURBT)

Immediate (within 6 hours) single instillation of mitomycin C (MMC) or epirubicin into the bladder following TURBT — destroys floating cancer cells and implanted cells, reducing 1-year recurrence risk by approximately 40%. Standard of care for low-risk and intermediate-risk NMIBC.

Intravesical BCG (Bacillus Calmette-Guérin)

The most effective intravesical agent for high-risk NMIBC — and the standard of care for all high-grade T1 and CIS. BCG is a live attenuated mycobacterial strain that triggers an intense local immune response within the bladder, activating T-cells, NK cells, and macrophages against tumour cells.

Protocol: Induction course (weekly instillations for 6 weeks); maintenance courses (weekly × 3) at months 3, 6, 12, 18, 24, 30, 36 — the optimal 3-year maintenance course reduces recurrence and progression versus induction alone.

• Reduces recurrence by approximately 30–40% over chemotherapy alone
• Reduces progression to MIBC by approximately 30–40%
• Side effects: dysuria, frequency, low-grade fever (BCG cystitis — treated symptomatically); BCG sepsis — rare systemic dissemination requiring anti-tuberculosis treatment; haematuria

BCG-unresponsive disease: tumours that recur or persist after adequate BCG — historically required cystectomy; newer options include pembrolizumab (PD-1 inhibitor: KEYNOTE-057 trial) and cretostimogene (oncolytic adenovirus), approved in some jurisdictions.

Surveillance Cystoscopy

After treatment of NMIBC, lifelong cystoscopic surveillance is mandatory — recurrence risk after TURBT is approximately 50–70% at 5 years for high-grade disease.

• Low-risk: flexible cystoscopy at 3 months, 12 months, then annually for 5 years
• High-risk: cystoscopy every 3 months for 2 years, every 6 months for 2 years, then annually indefinitely

Muscle-Invasive Bladder Cancer (MIBC)

Neoadjuvant Chemotherapy (NAC)

Cisplatin-based combination chemotherapy (MVAC — methotrexate, vinblastine, adriamycin, cisplatin; or gemcitabine + cisplatin) given before radical cystectomy — improves 5-year overall survival by approximately 5–8% (absolute) in cisplatin-eligible patients. NAC downstages the primary tumour and eradicates micrometastatic disease. Now standard of care before cystectomy for cT2–T4 MIBC in fit patients.

Radical Cystectomy

Removal of the entire bladder (and prostate + seminal vesicles in men; uterus, ovaries, and anterior vaginal wall in women) with bilateral pelvic lymph node dissection. The standard curative treatment for MIBC.

Urinary diversion — the bladder must be replaced; three options:

1. Orthotopic neobladder (ileal neobladder) — a reservoir constructed from the ileum, connected directly to the urethra, allowing voiding per urethra; provides best quality of life and continence; requires adequate urethral sphincter function; daytime continence ~90%, night-time continence ~75%
2. Ileal conduit (Bricker) — ureters anastomosed to a short segment of ileum, which exits as a stoma (urostomy) on the abdominal wall; simplest and most reliable; no internal reservoir; requires stoma bag
3. Continent cutaneous diversion (Indiana pouch, Mitrofanoff) — internal reservoir catheterised via a continent abdominal stoma; no bag; requires manual catheterisation every 4–6 hours

Robot-assisted radical cystectomy (RARC) — the da Vinci robotic system enables minimally invasive cystectomy with equivalent oncological outcomes to open surgery; reduced blood loss and faster recovery; urinary diversion can be performed intracorporeally or extracorporeally; available at specialist centres.

Complications: erectile dysfunction and retrograde ejaculation (men); sexual dysfunction and vaginal dryness (women); urinary complications (ureteric stricture, neobladder dysfunction); bowel complications.

Trimodality Therapy (Bladder-Preserving Approach)

For selected patients with T2 MIBC who refuse cystectomy or are unfit for surgery: complete TURBT + concurrent chemotherapy (cisplatin or 5-FU/mitomycin) + external beam radiotherapy. Bladder preservation achieved in approximately 40–50% of carefully selected patients with 5-year overall survival comparable to cystectomy in propensity-matched series. Requires close surveillance.

Metastatic/Advanced Bladder Cancer

First-line: cisplatin + gemcitabine chemotherapy — the standard regimen for cisplatin-eligible patients with metastatic TCC.

Immune checkpoint inhibitors (PD-1/PD-L1):

• Pembrolizumab (KEYNOTE-045) — second-line after platinum chemotherapy; improves overall survival vs chemotherapy
• Atezolizumab, nivolumab, durvalumab, avelumab — multiple approvals across first-line cisplatin-ineligible, maintenance, and second-line settings

Enfortumab vedotin (antibody-drug conjugate targeting Nectin-4) + pembrolizumab: EV-302 trial demonstrated median OS of 31.5 months vs 16.1 months with platinum-gemcitabine — a paradigm-changing result establishing EV+pembro as a new first-line standard for cisplatin-eligible patients.

FGFR inhibitors: erdafitinib — for FGFR3/FGFR2-altered metastatic urothelial carcinoma progressing after platinum.

Bladder Cancer Care in China

China's urology and oncology centres offer:

• Urgent haematuria assessment: flexible cystoscopy, CT urography, and urine cytology; blue-light (PDD) cystoscopy at specialist centres
• TURBT with muscle sampling: quality TURBT including detrusor muscle in the specimen; re-TURBT protocol for high-risk NMIBC; BCG induction and maintenance
• Radical cystectomy with neobladder: robotic cystectomy teams with intracorporeal neobladder reconstruction experience at major centres; full continence rehabilitation support
• Trimodality therapy: concurrent chemoradiotherapy bladder preservation programmes at radiation oncology centres
• Systemic therapy access: cisplatin + gemcitabine, pembrolizumab, enfortumab vedotin, erdafitinib
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from haematuria assessment through TURBT, intravesical therapy, surveillance, or surgical planning

Contact a ChinaMedicalTour care navigator to arrange a haematuria assessment, cystoscopy, or bladder cancer treatment consultation.

---

Medical content based on MSD Manuals and international bladder cancer guidelines (EAU, NCCN). Evidence reviewed 2025.

Frequently Asked Questions

Can overseas urological patients receive a preliminary review of imaging and lab results?

Yes. Multiparametric prostate MRI, urinary CT scans, ultrasound reports, and PSA or urinalysis findings can be reviewed through pre-consultation coordination with senior Chinese urologists.

What minimally invasive urological procedures are evaluated in Chinese tertiary centers?

Urology departments evaluate laser prostate enucleation (HoLEP/ThuLEP), flexible ureteroscopic stone lithotripsy, transurethral resections, and robotic laparoscopic urological surgery.

How are appointments and hospital fee quotations confirmed for international patients?

Hospital consultations and surgical schedules are confirmed directly with the department, with all medical fees paid directly to the treating public hospital according to published counter schedules.